Clinical Study Data Request Registered Users, Please Login

Find by:

Study ID:
Medicine:
Phase:

An Open-Label, Multi-Center Study to Investigate the Objective Response Rate, Safety, and Pharmacokinetics of GSK1120212, a MEK Inhibitor, in BRAF Mutation-positive Melanoma Subjects Previously Treated with or without a BRAF Inhibitor
trametinib
MEK113583
NCT01037127
Cancer
Phase 2
 
September 2013

Powered by ideaPoint, Inc.